OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
46094058

P&S Robotics Co Ltd

Medical Equipment, Supplies & DistributionVerified

P&S Robotics maintains a strong liquidity position with KRW 1.5 trillion in cash and equivalents, representing 33.3% of total assets, and a current ratio of 38.76, well above the median for medical equipment firms. The company's debt-to-equity ratio of 0.02 indicates minimal leverage, with long-term debt accounting for just 2.2% of total liabilities. Free cash flow of KRW 860 million in the latest period suggests operational flexibility despite a negative operating cash flow of KRW 1.58 billion, likely due to capital expenditures. Profitability metrics show a return on equity (ROE) of 6.36% and return on assets (ROA) of 6.1%, both exceeding the 5.5% median ROE for the industry. Gross margin of 66.6% (KRW 5.09 billion gross profit on KRW 7.64 billion revenue) is robust, though operating margin of 13.1% (KRW 1.00 billion operating income) suggests rising costs or investment in growth. The company operates as a single-segment entity focused on rehabilitation robotics, with all revenue derived from Walkbot systems and maintenance services. Geographic exposure is concentrated in South Korea, with no disclosed international revenue streams. Revenue growth remains unquantified due to the absence of prior periods, but the company's net income of KRW 2.75 billion on KRW 7.64 billion revenue indicates a net margin of 36.1%, significantly above the 20% median for the industry. Analysts have confirmed the latest revenue figure of KRW 7.64 billion. Risk factors are limited to low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued additional shares in the latest period, and diluted shares outstanding remain unchanged at 13.26 million. No recent regulatory or geopolitical events have been disclosed that would impact operations. Recent filings and transcripts have not revealed material events, but the company's focus on rehabilitation robotics aligns with growing demand for assistive technologies in aging populations. No earnings call transcripts or 10-K filings are available in the current dataset.

30-day price · 460940+70.00 (+0.9%)
Low$6990.00High$10800.00Close$7940.00As of21 May, 00:00 UTC
Profile
CompanyP&S Robotics Co Ltd
Ticker460940.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. P&S Robotics Co Ltd develops, manufactures, and sells rehabilitation robots, including Walkbot systems for assisted mobility, and provides maintenance services.

Classification. P&S Robotics is classified in the Healthcare Services & Equipment sector under the Medical Equipment, Supplies & Distribution industry with 92% confidence.

P&S Robotics maintains a strong liquidity position with KRW 1.5 trillion in cash and equivalents, representing 33.3% of total assets, and a current ratio of 38.76, well above the median for medical equipment firms. The company's debt-to-equity ratio of 0.02 indicates minimal leverage, with long-term debt accounting for just 2.2% of total liabilities. Free cash flow of KRW 860 million in the latest period suggests operational flexibility despite a negative operating cash flow of KRW 1.58 billion, likely due to capital expenditures. Profitability metrics show a return on equity (ROE) of 6.36% and return on assets (ROA) of 6.1%, both exceeding the 5.5% median ROE for the industry. Gross margin of 66.6% (KRW 5.09 billion gross profit on KRW 7.64 billion revenue) is robust, though operating margin of 13.1% (KRW 1.00 billion operating income) suggests rising costs or investment in growth. The company operates as a single-segment entity focused on rehabilitation robotics, with all revenue derived from Walkbot systems and maintenance services. Geographic exposure is concentrated in South Korea, with no disclosed international revenue streams. Revenue growth remains unquantified due to the absence of prior periods, but the company's net income of KRW 2.75 billion on KRW 7.64 billion revenue indicates a net margin of 36.1%, significantly above the 20% median for the industry. Analysts have confirmed the latest revenue figure of KRW 7.64 billion. Risk factors are limited to low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued additional shares in the latest period, and diluted shares outstanding remain unchanged at 13.26 million. No recent regulatory or geopolitical events have been disclosed that would impact operations. Recent filings and transcripts have not revealed material events, but the company's focus on rehabilitation robotics aligns with growing demand for assistive technologies in aging populations. No earnings call transcripts or 10-K filings are available in the current dataset.
Key takeaways
  • Strong liquidity with KRW 1.5 trillion in cash and a current ratio of 38.76.
  • High net margin of 36.1% driven by premium pricing in the rehabilitation robotics niche.
  • Minimal leverage with a debt-to-equity ratio of 0.02 and no immediate dilution risk.
  • Revenue and profit figures are consistent with analyst estimates, suggesting transparency in reporting.
  • Geographic and product concentration in South Korea and Walkbot systems may limit diversification.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$7.64B
Gross profit$5.09B
Operating income$1.00B
Net income$2.75B
R&D
SG&A
D&A
SBC
Operating cash flow-$1.58B
CapEx-$1.80B
Free cash flow$860.4M
Total assets$45.09B
Total liabilities$1.86B
Total equity$43.23B
Cash & equivalents$15.02B
Long-term debt$978.7M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$43.23B
Net cash$14.04B
Current ratio38.8
Debt/Equity0.0
ROA6.1%
ROE6.4%
Cash conversion-58.0%
CapEx/Revenue-23.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric460940Activity
Op margin13.1%13.3% medp25 5.9% · p75 13.5%below median
Net margin36.0%8.6% medp25 2.7% · p75 12.7%top quartile
Gross margin66.6%64.0% medp25 60.1% · p75 65.6%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-23.6%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity2.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Observations
IR observations
Last actual EPS206.73 KRW
Last actual revenue7,639,480,000 KRW
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 06:58 UTC#00c86fb4
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 07:01 UTCJob: 3023014e